[Lymph node diagnosis with imaging methods. An overview with special reference to recent developments in the area of MR contrast media].
The main problem in current lymph node imaging is the lack of reliable criteria for differential diagnosis between benign and malignant nodes, the main criterion being size. To reliably opacify all lymph nodes in the body, an intravenous contrast agent is therefore necessary. Two new contrast agents for MRI seem promising: lymphotropic iron oxides and Gadolinium DTPA-PGM. After intravenous administration these agents accumulate in phagocytic cells of normal lymph nodes but are excluded from nodes in which phagocytic activity is replaced. While iron oxides are already in clinical studies, GD-DTPA-PGM is in preclinical studies. Both agents seem to significantly improve the differential diagnosis between benign and malignant lymph nodes irrespective of size.
Mohr
U
U
Department of Radiology-Center for Molecular Imaging Research (CIMR), Massachusetts General Hospital, Boston, USA.
Weissleder
R
R
D003287:Contrast Media; D003952:Diagnostic Imaging; D005290:Ferric Compounds; D019786:Gadolinium DTPA; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis / Q000175:diagnosis* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D009942:Organometallic Compounds; D004369:Pentetic Acid / Q000031:analogs & derivatives; D012680:Sensitivity and Specificity
D003287:Contrast Media; D005290:Ferric Compounds; D009942:Organometallic Compounds; C088920:gadolinium-diethylenetriaminepentaacetic acid-cascade-polymer; C000499:ferric oxide; D004369:Pentetic Acid; D019786:Gadolinium DTPA
Lymphknotendiagnostik mit bildgebenden Verfahren. Ein Uberblick mit besonderer Berücksichtigung der letzten Entwicklungen im Bereich der MR-Kontrastmittel.